Outcomes of postoperative concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma

Archives of Otolaryngology - Head and Neck Surgery

Volumn 135, Issue 7, 2009, Pages 687-692

  Tanvetyanon, Tawee ^a,b   Qin, Dahui ^a   Padhya, Tapan ^a   McCaffrey, Judith ^a   Zhu, Weiwei ^a   Boulware, David ^a   DeConti, Ronald ^a   Trotti, Andy ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b 12902 Magnolia Dr ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DERMATITIS; DISEASE COURSE; DRUG TOLERABILITY; DYSPHAGIA; ECTROPION; EPIPHORA; FEMALE; FISTULA; HUMAN; LEUKOPENIA; MALE; MEDICAL RECORD REVIEW; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAROTIDECTOMY; POSTOPERATIVE CARE; PROGRESSION FREE SURVIVAL; RADIATION DERMATITIS; RADIATION DOSE; SALIVARY GLAND CARCINOMA; SKIN EXFOLIATION; SKIN FIBROSIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TRISMUS; ULCER; VOMITING; XEROSTOMIA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LYMPH NODE EXCISION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PAROTID NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; SALIVARY GLAND NEOPLASMS; SURVIVAL ANALYSIS;

EID: 67651115606     PISSN: 08864470     EISSN: 08864470     Source Type: Journal    
DOI: 10.1001/archoto.2009.70     Document Type: Article

References (19)

1. Spiro RH. Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg. 1986;8(3):177-184.
2. Aro K, Leivo I, Mäkitie AA. Management and outcome of patients with mucoepidermoid carcinoma of major salivary gland origin: a single institution's 30-year experience. Laryngoscope. 2008;118(2):258-262. (Pubitemid 351640197)
3. Chen AM, Granchi PJ, Garcia J, Bucci MK, Fu KK, Eisele DW. Local-regional recurrence after surgery without postoperative irradiation for carcinomas of the major salivary glands: implications for adjuvant therapy. Int J Radiat Oncol Biol Phys. 2007;67(4):982-987. (Pubitemid 46320095)
4. Terhaard CH, Lubsen H, Rasch CR, et al; Dutch Head and Neck Oncology Cooperative Group. The role of radiotherapy in the treatment of malignant salivary gland tumors. Int J Radiat Oncol Biol Phys. 2005;61(1):103-111.
5. Chen AM, Bucci MK, Quivey JM, Garcia J, Eisele DW, Fu KK. Long-term outcome of patients treated by radiation therapy alone for salivary gland carcinomas. Int J Radiat Oncol Biol Phys. 2006;66(4):1044-1050. (Pubitemid 44633522)
6. Piccirillo JF, Costas I, Reichman ME. Cancers of the head and neck. In: Ries LAG, Young JL, Keel GE, EisnerMP,Lin YD, Horner M-J, eds. SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001. Bethesda, MD: National Cancer Institute, SEER Program; 2007:7-22. NIH publication 07-6215.
7. Bernier J, Domenge C, Ozsahin M, et al; European Organization for Research and Treatment of Cancer Trial 22931. Post-operative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19):1945-1952.
8. Cooper JS, Pajak TF, Forastiere AA, et al; Radiation Therapy Oncology Group 9501/Intergroup. Postoperative concurrent radiotherapy and chemotherapy for highrisk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350(19):1937-1944.
9. Licitra L, Marchini S, Spinazzè S, et al. Cisplatin in advanced salivary gland carcinoma: a phase II study of 25 patients. Cancer. 1991;68(9):1874-1877.
10. Green FL, Page DL, Fleming ID, et al; American Joint Committee on Cancer. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer Verlag; 2002.
11. Goode RK, Auclair PL, Ellis GL. Mucoepidermoid carcinoma of the major salivary glands: clinical and histopathologic analysis of 234 cases with evaluation of grading criteria. Cancer. 1998;82(7):1217-1224.
12. Social Security death index. http://ssdi.rootsweb.com. Accessed October 20, 2008.
13. Carrillo JF, Vázquez R, Ramírez-Ortega MC, Cano A, Ochoa-Carrillo FJ, Oñate-Ocaña LF. Multivariate prediction of the probability of recurrence in patients with carcinoma of the parotid gland. Cancer. 2007;109(10):2043-2051. (Pubitemid 46744199)
14. Kam MK, Leung SF, Zee B, et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol. 2007;25(31):4873-4879. (Pubitemid 350220416)
15. Gilbert J, Li Y, Pinto HA, et al. Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. Head Neck. 2006;28(3):197-204. (Pubitemid 43269885)
16. Airoldi M, Fornari G, Pedani F, et al. Paclitaxel and carboplatin for recurrent salivary gland malignancies. Anticancer Res. 2000;20(5C):3781-3783. (Pubitemid 32002275)
17. Airoldi M, Pedani F, Succo G, et al. Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer. 2001;91(3):541-547. (Pubitemid 32105699)
18. Jaehne M, Roeser K, Jaekel T, Schepers JD, Albert N, Löning T. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer. 2005;103(12):2526-2533. (Pubitemid 40800531)
19. Nashed M, Casasola RJ. Biological therapy of salivary duct carcinoma. J Laryngol Otol. 2009;123(2):250-252.